Prometheus Biosciences Inc

-0.65 (-2.19%)
Earnings Announcements

Prometheus Biosciences Reports Q1 2022 Results

Published: 05/12/2022 20:10 GMT
Prometheus Biosciences Inc (RXDX) - Prometheus Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress.
Prometheus Biosciences- As of Mar 31, 2022, Prometheus Biosciences Had Cash and Cash Equivalents of $227.0 Million, Compared to $257.3 Million at End of Q4 2021.
Qtrly Net Loss per Share, Basic and Diluted $0.82.
Revenue is expected to be $0.55 Million
Adjusted EPS is expected to be -$0.90

Next Quarter Revenue Guidance is expected to be $0.55 Million
Next Quarter EPS Guidance is expected to be -$0.93

More details on our Analysts Page.